CRISPR Therapeutics (NASDAQ:CRSP) Given New $82.00 Price Target at Citigroup

CRISPR Therapeutics (NASDAQ:CRSP) had its price objective lowered by stock analysts at Citigroup from $89.00 to $82.00 in a research report issued on Tuesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Citigroup’s price objective would indicate a potential upside of 56.82% from the company’s current price.

CRSP has been the subject of several other research reports. Barclays boosted their price target on shares of CRISPR Therapeutics from $55.00 to $56.00 and gave the company an “equal weight” rating in a report on Wednesday, February 12th. StockNews.com upgraded shares of CRISPR Therapeutics to a “sell” rating in a report on Thursday, February 13th. Royal Bank of Canada reduced their price target on shares of CRISPR Therapeutics from $53.00 to $48.00 and set a “sector perform” rating for the company in a report on Wednesday, February 12th. Morgan Stanley boosted their price target on shares of CRISPR Therapeutics from $30.00 to $32.00 and gave the company an “underweight” rating in a report on Friday. Finally, Stifel Nicolaus cut their price objective on shares of CRISPR Therapeutics from $53.00 to $49.00 and set a “hold” rating on the stock in a research report on Thursday, February 13th. Two equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and twelve have given a buy rating to the company. According to MarketBeat.com, CRISPR Therapeutics currently has a consensus rating of “Hold” and an average target price of $74.40.

CRISPR Therapeutics Stock Up 5.2 %

CRSP traded up $2.57 on Tuesday, reaching $52.29. 6,006,934 shares of the company traded hands, compared to its average volume of 2,305,073. CRISPR Therapeutics has a one year low of $36.52 and a one year high of $91.10. The firm has a fifty day simple moving average of $41.89 and a two-hundred day simple moving average of $45.98. The company has a market cap of $4.46 billion, a P/E ratio of -18.48 and a beta of 1.67.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings data on Tuesday, February 11th. The company reported ($0.44) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.15) by $0.71. CRISPR Therapeutics had a negative net margin of 118.13% and a negative return on equity of 12.15%. On average, equities analysts forecast that CRISPR Therapeutics will post -5.08 earnings per share for the current year.

Insider Buying and Selling at CRISPR Therapeutics

In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 15,000 shares of CRISPR Therapeutics stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $55.10, for a total transaction of $826,500.00. Following the completion of the sale, the chief executive officer now directly owns 181,540 shares in the company, valued at approximately $10,002,854. The trade was a 7.63 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Company insiders own 4.10% of the company’s stock.

Institutional Trading of CRISPR Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the business. Sunbelt Securities Inc. lifted its stake in CRISPR Therapeutics by 108.6% during the 4th quarter. Sunbelt Securities Inc. now owns 6,165 shares of the company’s stock valued at $238,000 after acquiring an additional 3,210 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in CRISPR Therapeutics by 2.1% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 690,191 shares of the company’s stock valued at $27,166,000 after acquiring an additional 13,865 shares during the period. Woodline Partners LP lifted its stake in shares of CRISPR Therapeutics by 1.6% in the 4th quarter. Woodline Partners LP now owns 101,600 shares of the company’s stock valued at $3,999,000 after purchasing an additional 1,600 shares during the period. Westwood Holdings Group Inc. lifted its stake in shares of CRISPR Therapeutics by 18.1% in the 4th quarter. Westwood Holdings Group Inc. now owns 53,102 shares of the company’s stock valued at $2,090,000 after purchasing an additional 8,120 shares during the period. Finally, Two Sigma Advisers LP lifted its stake in shares of CRISPR Therapeutics by 50.4% in the 4th quarter. Two Sigma Advisers LP now owns 84,800 shares of the company’s stock valued at $3,338,000 after purchasing an additional 28,400 shares during the period. 69.20% of the stock is currently owned by institutional investors and hedge funds.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.